Cenicriviroc

DRUG9 trials

Sponsors

Tobira Therapeutics, Inc., University of Hawaii, Allergan, QuantumLeap Healthcare Collaborative

Conditions

AIDS Dementia ComplexCOVID-19HIV-1-Associated Cognitive Motor ComplexHIV-infection/AIDSHealthyHepatic ImpairmentHuman Immunodeficiency VirusLiver Cirrhosis

Phase 1

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

CompletedNCT01827540

Tobira Therapeutics, Inc.HIV-infection/AIDS

Start: 2013-03-31End: 2013-05-31Updated: 2014-04-09

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

CompletedNCT02342067

Tobira Therapeutics, Inc.Healthy

Start: 2014-12-31End: 2015-04-30Updated: 2015-05-12

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

CompletedNCT02684799

Tobira Therapeutics, Inc.Healthy

Start: 2016-01-31End: 2016-04-11Updated: 2017-11-24

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

CompletedNCT03376841

AllerganHepatic Impairment

Start: 2017-06-06End: 2017-12-17Updated: 2018-01-11

Phase 2

Effect of Cenicriviroc on HIV Neurocognitive Impairment

CompletedNCT02128828

University of HawaiiAIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus

Start: 2014-04-30End: 2016-06-30Updated: 2020-08-20

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

CompletedNCT02217475

Tobira Therapeutics, Inc.Nonalcoholic Steatohepatitis

Start: 2014-09-18End: 2017-06-22Updated: 2019-05-10

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

TerminatedNCT03059446

Tobira Therapeutics, Inc.Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis

Start: 2017-02-14End: 2021-01-05Updated: 2022-02-02

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruitingNCT04488081

QuantumLeap Healthcare CollaborativeCOVID-19

Start: 2020-07-31End: 2030-07-31Target: 1500Updated: 2026-03-16

Phase 3

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

TerminatedNCT03028740

Tobira Therapeutics, Inc.Nonalcoholic Steatohepatitis

Start: 2017-04-05End: 2021-03-09Updated: 2022-03-10

Related Papers

Simulation-Based Bayesian Predictive Probability of Success for Interim Monitoring of Clinical Trials With Competing Event Data: Two Case Studies.

2026-01-011 citations

Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.

2025-10-29

Anti-CD14 Treatment in Patients With Severe COVID-19 Clinical and Biological Effects in a Phase 2 Randomized Open-Label Adaptive Platform Clinical Trial

CHEST Critical Care2024-12-092 citations

Phosphatidylethanol measures in patients with severe <scp>COVID</scp>‐19‐associated respiratory failure identify a subset with alcohol misuse

Alcohol Clinical and Experimental Research2024-11-26

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

Clinical Gastroenterology and Hepatology2023-04-13125 citations

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial.

2023-03-0318 citations

I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations

BMJ Open2022-06-0125 citations

Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development.

2021-12-2232 citations

Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population

Journal of Hepatology2021-08-2659 citations

Coronary computed tomography angiography and [<sup>15</sup>O]H<sub>2</sub>O positron emission tomography perfusion imaging for the assessment of coronary artery disease.

2020-08-011 citations

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

Hepatology2020-01-13344 citations

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

Contemporary Clinical Trials2019-12-24123 citations

2942 Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design

The American Journal of Gastroenterology2019-10-012 citations

An update on the pharmacological treatment of nonalcoholic fatty liver disease: Beyond lifestyle modifications

Clinical Liver Disease2018-04-0139 citations

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

PLoS ONE2016-06-27306 citations

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

Clinical and Translational Science2016-05-1251 citations

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.

2016-03-02152 citations

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

AIDS2015-12-0487 citations